In a report published by Piper Jaffray, Vertex Pharmaceuticals' VRTX shares have surged.
Piper Jaffray reported that shares of VRTX have surged 45.8% this year based on positive STRIVE data in cystic fibrosis (CF) and ahead of likely Telaprevir approval in HCV by the May 23rd PDUFA date. “We continue to look for a busy month of March with Phase II VX-765 data in epilepsy and Phase II combo data of Telaprevir + VX-222 at the International Liver Congress in Berlin. Positive data from either study could provide upside to our current $52 price target.”
Vertex Pharmaceuticals closed yesterday at $51.07.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.